Matinas BioPharma Holdings (MTNB) Operating Leases (2018 - 2026)

Matinas BioPharma Holdings (MTNB) has 9 years of Operating Leases data on file, last reported at $464000.0 in Q1 2026.

• Operating Leases for Q1 2026 came in at $464000.0, down 82.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $464000.0 (down 82.8% YoY), and the FY2025 annual result was $653000.0, down 77.3% from the prior year.
• Operating Leases eased to $464000.0 in Q1 2026 per MTNB's latest filing, from $653000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $4.6 million in Q1 2022 and troughed at $464000.0 in Q1 2026.
• A 5-year average of $2.9 million and a median of $2.9 million in 2023 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2026: Operating Leases jumped 41.6% in 2022, then slumped 82.8% in 2026.
• A 5-year view of Operating Leases shows it stood at $4.1 million in 2022, then dropped by 29.74% to $2.9 million in 2023, then changed by 0.0% to $2.9 million in 2024, then sank by 77.3% to $653000.0 in 2025, then fell by 28.94% to $464000.0 in 2026.
• Business Quant data shows MTNB's Operating Leases at $464000.0 in Q1 2026, $653000.0 in Q4 2025, and $1.5 million in Q3 2025.